
Javier Arranz-NicolÃ;s

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9421262/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Diacylglycerol kinase α inhibition cooperates with PD-1-targeted therapies to restore the T cell activation program. Cancer Immunology, Immunotherapy, 2021, 70, 3277-3289.	4.2	14
2	Biological regulation of diacylglycerol kinases in normal and neoplastic tissues: New opportunities for cancer immunotherapy. Advances in Biological Regulation, 2020, 75, 100663.	2.3	12
3	Diacylglycerol kinase ζ limits IL-2-dependent control of PD-1 expression in tumor-infiltrating T lymphocytes. , 2020, 8, e001521.		10
4	Diacylglycerol Kinase Malfunction in Human Disease and the Search for Specific Inhibitors. Handbook of Experimental Pharmacology, 2019, 259, 133-162.	1.8	12
5	Diacylglycerol kinase control of protein kinase C. Biochemical Journal, 2019, 476, 1205-1219.	3.7	34
6	Transcriptional Activity of FOXO Transcription Factors Measured by Luciferase Assays. Methods in Molecular Biology, 2019, 1890, 91-102.	0.9	3
7	Diacylglycerol kinase \hat{I}_{\pm} inactivation is an integral component of the costimulatory pathway that amplifies TCR signals. Cancer Immunology, Immunotherapy, 2018, 67, 965-980.	4.2	27
8	Predominant contribution of DGKζ over DGKα in the control of PKC/PDKâ€lâ€regulated functions in T cells. Immunology and Cell Biology, 2017, 95, 549-563.	2.3	23
9	Diacylglycerol kinases in cancer. Advances in Biological Regulation, 2017, 63, 22-31.	2.3	56